Evidence map›Paper›PMID 24156479›Full record

ArticleRetrovirology2013

Natural regulatory T cells inhibit production of cytotoxic molecules in CD8⁺ T cells during low-level Friend retrovirus infection.

Gennadiy Zelinskyy, Tanja Werner, Ulf Dittmer

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Limited Foxp3Frontiers in immunology · 2018
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Gennadiy ZelinskyyInstitut für Virologie des Universitätsklinikums Essen, Universität Duisburg-Essen, Hufelandstr, 55, 45122 Essen, Germany. gennadiy.zelinskyy@uni-due.de.
Tanja Werner
Ulf Dittmer
University of Duisburg-Essen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCytotoxic T cells (CTL) play a central role in the control of viral infections. Their antiviral activity can be mediated by at least two cytotoxic pathways, namely the granule exocytosis pathway, involving perforin and granzymes, and the Fas-FasL pathway. It was shown that the level of Friend retrovirus (FV) replication determines the cytotoxic pathway for the control of viral infection. In low-level infection only the Fas pathway is active, whereas cytotoxic molecules are not produced. In the current study, we elucidate the role of CD4⁺ regulatory T cells (Tregs) in suppressing the exocytosis pathway during an asymptomatic low-level infection.

findingsWe show that even a low-level retrovirus infection induced a strong activation and proliferation of natural Tregs. The expanded Tregs suppressed the proliferation of virus-specific CD8⁺ T cells and the production of cytotoxic molecules by these cells. Not surprisingly, the in vivo killing activity of these CD8⁺ T cells was rather weak. Selective depletion of Foxp3⁺ Tregs resulted in de novo granzyme production and augmented virus-specific in vivo killing, but did not affect the low-level virus replication.

conclusionsExpanded natural Tregs determined the cytotoxic pathways of virus-specific effector CD8⁺ T cells during the acute phase of retroviral infection.

Indexed as

AnimalsCD8-Positive T-LymphocytesCell ProliferationFriend murine leukemia virusMice, Inbred C57BLRetroviridae InfectionsT-Lymphocytes, CytotoxicT-Lymphocytes, Regulatory

Identifiers

PMID24156479
PMCPMC4015423
OpenAlexW2144278364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.